Market closed
Allogene Therapeutics/$ALLO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Allogene Therapeutics
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
Ticker
$ALLO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
233
Website
ALLO Metrics
BasicAdvanced
$455M
-
-$1.54
0.84
-
Price and volume
Market cap
$455M
Beta
0.84
52-week high
$5.78
52-week low
$1.32
Average daily volume
7.5M
Financial strength
Current ratio
9.346
Quick ratio
9.038
Long term debt to equity
18.358
Total debt to equity
19.951
Interest coverage (TTM)
-2,688.56%
Management effectiveness
Return on assets (TTM)
-25.82%
Return on equity (TTM)
-54.15%
Valuation
Price to revenue (TTM)
9,313.305
Price to book
0.98
Price to tangible book (TTM)
0.98
Price to free cash flow (TTM)
-1.835
Growth
Revenue change (TTM)
26.47%
Earnings per share change (TTM)
-32.57%
3-year revenue growth (CAGR)
-89.62%
3-year earnings per share growth (CAGR)
-6.44%
What the Analysts think about ALLO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Allogene Therapeutics stock.
ALLO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ALLO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ALLO News
AllArticlesVideos
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
Seeking Alpha·6 hours ago
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
GlobeNewsWire·2 weeks ago
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Allogene Therapeutics stock?
Allogene Therapeutics (ALLO) has a market cap of $455M as of February 25, 2025.
What is the P/E ratio for Allogene Therapeutics stock?
The price to earnings (P/E) ratio for Allogene Therapeutics (ALLO) stock is 0 as of February 25, 2025.
Does Allogene Therapeutics stock pay dividends?
No, Allogene Therapeutics (ALLO) stock does not pay dividends to its shareholders as of February 25, 2025.
When is the next Allogene Therapeutics dividend payment date?
Allogene Therapeutics (ALLO) stock does not pay dividends to its shareholders.
What is the beta indicator for Allogene Therapeutics?
Allogene Therapeutics (ALLO) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.